Clinical Guidelines & Medical Policies
To access the guidelines and training materials below, please email services@ppsanalytics.com
Table of Contents:
UROLOGY
- APC Clinical Guideline
- BPH Clinical Guideline
- Gonadotropin-Releasing Hormone Agonists – Injectable Long-Acting Products UM Medical De-Identified
- Gonadotropin-Releasing Hormone Agonists – Injectable Long-Acting Products Utilization Management Medical Policy
- GnRH Agonists – Lupron Depot and Lupaneta MA Policy
- GnRH Agonists – Injectable Long-Acting Products MA Policy
- OAB Clinical Guideline
- Peyronie’s Disease Clinical Guideline
- Botulinum Toxins – Medicare Advantage Medical Utilization Review Policies
- Localized to High-Risk Biochemically Recurrent Prostate Cancer Patient Playbook
- PARP Inhibitors Resource
GASTROENTEROLOGY
- IBD 5-ASA Guide
- IBD Pathway
- IBD Advanced Therapy Guide
- IBD Patient Pathway Education
- IBD Patient Pathway Intake Form
- IBD Steroid Guide
- Inflammatory Conditions – Cimzia UM Medical De-Identified
- Inflammatory Conditions – Entyvio Intravenous UM Medical De-Identified
- Inflammatory Conditions – Infliximab Products UM Medical De-Identified
- Inflammatory Conditions – Infliximab Products Utilization Management Medical Policy
- Inflammatory Conditions – Infliximab Products Medicare Advantage Medical Utilization Review Policy
- Inflammatory Conditions – Simponi Aria UM Medical De-Identified
- Inflammatory Conditions – Skyrizi Intravenous UM Medical De-Identified
- Inflammatory Conditions – Stelara Intravenous UM Medical De-Identified
- Inflammatory Conditions – Tocilizumab Intravenous Products Utilization Management Medical Policy
- Inflammatory Conditions – Stelara Subcutaneous Prior Authorization Policy with Dosing
- Inflammatory Conditions – Orencia Intravenous Utilization Management Medical Policy
- Inflammatory Conditions – Cosentyx Intravenous Utilization Management Medical Policy
- Inflammatory Conditions – Ilumya Utilization Management Medical Policy
- Inflammatory Conditions – Omvoh Utilization Management Medical Policy
- MASLD Pathway
RHEUMATOLOGY
- Axial Spondyloarthritis (axSpA) Clinical Guideline
- Biosimilars in Rheumatology Clinical Guideline
- GOUT Clinical Guideline
- Hyaluronic Acid Derivatives (Intraarticular) Utilization Management Medical Policy
- Hyaluronic Acid Derivatives (Intraarticular) Medicare Advantage Medical Utilization Review Policy
- Hyaluronic Acid Derivatives (Intraarticular) Medicare Advantage Medical Utilization Review Policy
- Hyaluronic Acid Derivatives (Intraarticular) Medicare Advantage Medical Utilization Review Policy
- Inflammatory Conditions – Cimzia Utilization Management Medical Policy
- Inflammatory Conditions – Infliximab Products Utilization Management Medical Policy
- Inflammatory Conditions – Infliximab Products Medicare Advantage Medical Utilization Review Policy
- Inflammatory Conditions – Simponi Aria Utilization Management Medical Policy
- Inflammatory Conditions – Tocilizumab Intravenous Products Utilization Management Medical Policy
- Inflammatory Conditions – Stelara Subcutaneous Prior Authorization Policy with Dosing
- Inflammatory Conditions – Orencia Intravenous Utilization Management Medical Policy
- Inflammatory Conditions – Cosentyx Intravenous Utilization Management Medical Policy
- Inflammatory Conditions – Ilumya Utilization Management Medical Policy
- Inflammatory Conditions – Omvoh Utilization Management Medical Policy
- Osteoarthritis of the Knee Clinical Guideline
- Osteoporosis Clinical Guideline
- Psoriatic Arthritis (PsA) Clinical Guideline
- Rheumatoid Arthritis Clinical Guideline
- Systemic Lupus Erythematosus Clinical Guideline
- Ultrasound in Rheumatological Settings Clinical Guideline
- Women’s Reproductive Health & Rheumatic Diseases Clinical Guideline
- Rituximab Intravenous Products – Utilization Management Medical Policies
- Oncology (Injectable) – Rituxan Hycela Utilization Management Medical Policy
Links
© Copyright 2024 Specialty Networks